Search Results for keywords:"Drug Enforcement Administration"

Globyz Pharma, LLC has applied to the Drug Enforcement Administration (DEA) for registration as an importer of controlled substances for analytical testing. The application does not authorize any other activities, such as importing FDA-approved finished dosage forms for sale. Interested parties, including registered manufacturers, can submit comments or objections, or request a hearing regarding this application by March 26, 2021. The DEA's decision will be based on alignment with legal requirements under 21 U.S.C. 952(a)(2).

The Drug Enforcement Administration (DEA) has announced that Sterling Wisconsin, LLC applied to register as a bulk manufacturer of certain controlled substances, specifically synthetic versions of Marihuana Extract, Marihuana, and Tetrahydrocannabinols. Interested parties can submit comments or objections electronically or request a hearing until May 27, 2025. The application was filed on January 30, 2025, and comments should be submitted via the Federal eRulemaking Portal as instructed.

Noramco has submitted an application to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of controlled substances. The company specifically plans to produce active pharmaceutical ingredients, including synthetic marihuana and tetrahydrocannabinols. Individuals or organizations can submit comments or objections to this application by March 25, 2025, through the Federal eRulemaking Portal. The announcement provides further details about the application and the procedures for submitting feedback.

The Drug Enforcement Administration (DEA) sought to revoke two registrations of Jason Weakley, a registered nurse and advanced practice registered nurse, because he was not authorized to handle controlled substances in Vermont and New Hampshire. Weakley's nursing licenses in both states had expired and remained suspended. He was informed of his right to a hearing but did not request one, leading to a default judgment against him. Consequently, the DEA revoked his registrations, preventing him from handling controlled substances and from renewing or applying for new registrations in these states.

The Drug Enforcement Administration (DEA) has revoked Rachel Jackson's DEA Certificate of Registration because she is not licensed to handle controlled substances in Maine. Jackson voluntarily surrendered her Maine physician assistant license, making her ineligible to practice or register with the DEA. Despite being alerted about the situation and the chance to request a hearing, Jackson did not respond, leading to a default determination and subsequent action to revoke her registration. The order for revocation is effective from April 21, 2025.

The Drug Enforcement Administration (DEA) has announced that North Star Holdings California, LLC, has applied to become a registered bulk manufacturer of marihuana, a Schedule I controlled substance. This application is part of a DEA program that regulates the cultivation of marihuana for scientific and medical research purposes. The DEA will review this and similar applications to ensure compliance with relevant laws and regulations, ensuring that adequate measures are in place to prevent illegal distribution. Interested parties may submit comments or objections to the DEA regarding this application before April 19, 2021.

The Department of Justice's Drug Enforcement Administration (DEA) is seeking public comments on a new information collection proposal. They aim to revise existing forms (DEA Forms 224 and 224A) to include emergency medical services (EMS) agencies under the Controlled Substances Act. This change would allow EMS agencies to register to handle controlled substances in line with state law. The comment period is open for 30 days, during which people can share their thoughts on the proposal's necessity, accuracy, and possible burden on those required to respond.

The Drug Enforcement Administration (DEA) revoked the registration of Hazem Barmada, M.D., allowing him to handle controlled substances in Mississippi because he no longer has a valid medical license in the state. The Mississippi State Board of Medical Licensure had accepted his voluntary surrender of the license in 2021, making him ineligible to practice medicine and handle controlled substances there. As holding a valid state license is necessary for DEA registration, Dr. Barmada’s registration was revoked, and any pending applications related to it were denied. This decision will take effect on April 21, 2025.

The Drug Enforcement Administration (DEA) has revoked the DEA registration of Xubex Community Pharmacy in Casselberry, Florida. This decision was made because the pharmacy dispensed controlled substances, specifically Schedule II drugs like oxycodone and hydromorphone, without prescriptions. The DEA considered these actions a threat to public health and safety, demonstrating that the pharmacy cannot be trusted to comply with legal requirements. Furthermore, the pharmacy did not request a hearing to dispute these conclusions, leading to the default revocation of its registration.

The Drug Enforcement Administration (DEA) decided to revoke the DEA Certificate of Registration for Dr. Willard J. Davis, a doctor in Texas, because he lost his state license to practice medicine, which means he can no longer handle controlled substances legally in Texas. The Texas Medical Board suspended Dr. Davis's medical license on May 16, 2024, and it remained suspended at the time of the decision. Since having a valid state medical license is necessary to maintain DEA registration for dispensing controlled substances, his registration was revoked, and any pending applications related to the registration were denied. This decision will be effective starting April 28, 2025.